These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19128228)

  • 1. Drugs designed to improve endothelial function: effects on erectile dysfunction.
    Shindel AW; Kishore S; Lue TF
    Curr Pharm Des; 2008; 14(35):3758-67. PubMed ID: 19128228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins and erectile dysfunction: a critical summary of current evidence.
    La Vignera S; Condorelli RA; Vicari E; Calogero AE
    J Androl; 2012; 33(4):552-8. PubMed ID: 22052777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelial effects of drugs designed to treat erectile dysfunction.
    Aversa A; Caprio M; Rosano GM; Spera G
    Curr Pharm Des; 2008; 14(35):3768-78. PubMed ID: 19128229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy.
    Imprialos KP; Stavropoulos K; Doumas M; Tziomalos K; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2018 Jan; 16(2):130-142. PubMed ID: 28595561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins.
    Miner M; Billups KL
    J Sex Med; 2008 May; 5(5):1066-1078. PubMed ID: 18331271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment.
    Pegge NC; Twomey AM; Vaughton K; Gravenor MB; Ramsey MW; Price DE
    Diabet Med; 2006 Aug; 23(8):873-8. PubMed ID: 16911625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The triad: erectile dysfunction--endothelial dysfunction--cardiovascular disease.
    Vlachopoulos C; Ioakeimidis N; Terentes-Printzios D; Stefanadis C
    Curr Pharm Des; 2008; 14(35):3700-14. PubMed ID: 19128223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease.
    Ganz P
    Am J Cardiol; 2005 Dec; 96(12B):8M-12M. PubMed ID: 16387559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDE5 inhibitors: targeting erectile dysfunction in diabetics.
    Francis SH; Corbin JD
    Curr Opin Pharmacol; 2011 Dec; 11(6):683-8. PubMed ID: 21924956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoring the dysfunctional endothelium.
    Osto E; Coppolino G; Volpe M; Cosentino F
    Curr Pharm Des; 2007; 13(10):1053-68. PubMed ID: 17430168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
    Sommer F; Schulze W
    World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Losartan, an Angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats.
    Yang R; Yang B; Wen Y; Fang F; Cui S; Lin G; Sun Z; Wang R; Dai Y
    J Sex Med; 2009 Mar; 6(3):696-707. PubMed ID: 19175863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment options for erectile dysfunction in patients with diabetes mellitus.
    Basu A; Ryder RE
    Drugs; 2004; 64(23):2667-88. PubMed ID: 15537369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases.
    Cai Z; Zhang J; Li H
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):119-128. PubMed ID: 30675707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse.
    Jin HR; Kim WJ; Song JS; Piao S; Tumurbaatar M; Shin SH; Choi MJ; Tuvshintur B; Song KM; Kwon MH; Yin GN; Koh GY; Ryu JK; Suh JK
    J Sex Med; 2010 Nov; 7(11):3635-46. PubMed ID: 20584113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasculogenic erectile dysfunction: newer therapeutic strategies.
    Siroky MB; Azadzoi KM
    J Urol; 2003 Aug; 170(2 Pt 2):S24-9; discussion S29-30. PubMed ID: 12853769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid lowering agents and the endothelium: an update after 4 years.
    Tziomalos K; Athyros VG; Karagiannis A; Mikhailidis DP
    Curr Vasc Pharmacol; 2012 Jan; 10(1):33-41. PubMed ID: 22112353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebivolol dilates human penile arteries and reverses erectile dysfunction in diabetic rats through enhancement of nitric oxide signaling.
    Angulo J; Wright HM; Cuevas P; González-Corrochano R; Fernández A; Cuevas B; La Fuente JM; Gupta S; Sáenz de Tejada I
    J Sex Med; 2010 Aug; 7(8):2681-97. PubMed ID: 20214719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracavernous delivery of stromal vascular fraction restores erectile function through production of angiogenic factors in a mouse model of cavernous nerve injury.
    Song KM; Jin HR; Park JM; Choi MJ; Kwon MH; Kwon KD; Batbold D; Yin GN; Kim WJ; Koh GY; Ryu JK; Suh JK
    J Sex Med; 2014 Aug; 11(8):1962-73. PubMed ID: 24902866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of endothelial cell function to erectile dysfunction: implications for treatment.
    Guay AT
    Am J Cardiol; 2005 Dec; 96(12B):52M-56M. PubMed ID: 16387568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.